Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

uniQure is a promising, yet high-risk investment opportunity. With the potential to address devastating diseases with its gene therapy treatments, the company has a strong pipeline and positive outlook. Continued progress and potential regulatory validation in the UK for AMT-130, as well as upcoming Phase 1/2a trial data for AMT-260, could serve as near-term catalysts for the company. However, there are financial and clinical risks inherent in investing in a clinical-stage company with no revenue-generating products on the market. Investors must carefully weigh the potential for success against these risks when considering investment in uniQure's stock.

Bears say

uniQure is a gene therapy company with a focus on developing treatments for genetic and other debilitating diseases. Despite strong collaborations and a diverse pipeline, there is a high level of risk associated with the company's clinical trials and potential regulatory challenges. Financial concerns, such as the need for additional funding, further exacerbate the company's risk profile. Additionally, intellectual property disputes and stock price volatility are potential risks that could affect the achievement of the current target price.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.